Publication
First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.
Michael Wang, Marc Hoffmann, Tomasz Wrobel, Marek Trneny, David Belada, Fatih Demirkan, Panayiotis Panayiotidis, Wojciech Jurczak, Pier Luigi Zinzani, Mary-Margaret Keating, Sung-Soo Yoon, Miklós Egyed, Constantine S Tam, Nathalie A Johnson, Edith Szafer-Glusman, Jennifer Lin, James P Dean, Jutta K Neuenburg, Gottfried von Keudell
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
The phase 3 SYMPATICO study included an open-label cohort to evaluate first-line ibrutinib plus venetoclax in patients with nonblastoid mantle cell lymphoma (MCL) aged ≥65 years (n = 65) or ≥18 years with a TP53 mutation (TP53m; n = 11). Eligible patients received oral ibrutinib 560 mg once daily…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT03112174registry_reference1.00
Registered trialsNCT03112174
Curated evidence
Evidence citing this paper (0)
Data not yet available